Cavendish sees significant upside in IXICO as surging order book and £10m raise point to growth inflexion

Cavendish has retained its buy rating and 26p price target on IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) following a first-half trading update that the broker described as demonstrating strong continued revenue growth, with the neuroscience imaging and analytics company trading in line with full-year expectations. The company reported first-half revenues expected to reach £3.9 million, up 23% year on year, driven by new contract wins, extensions and increased biomarker analysis activity, the measurement of biological indicators used to track neurological disease progression in clinical trials.